Aarhus, Denmark, 13 May 2025 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with neuromuscular diseases, today announces ...
When the adrenal gland produces too much aldosterone, this often leads to high blood pressure and kidney damage (hyperaldosteronism). It has only recently emerged that several patients harbor a ...
Bartter syndrome type I NKCC2 +++ Perinatal Polyuria, hypochloremia, alkalosis, hypokalemia, nephrocalcinosis Bartter syndrome type II ROMK +++ Perinatal Polyuria, hypochloremia, alkalosis, ...
Over-production of nitric oxide and ion disturbance are involved in neuronal apoptosis around the ischemic area following ischemic brain injury. Prof. Quanzhong Chang and team from Zhuhai Campus of ...
NMD Pharma ApS has described chloride channel protein 1 (CLCN1; ClC-1) channel blockers reported to be useful for the treatment of myasthenia gravis, Lambert-Eaton syndrome, critical illness myopathy, ...
NMD Pharma to present compelling preclinical data highlighting the potential of ClC-1 ion channel inhibition to improve disease symptoms and progression in MuSK myasthenia gravis at the MGFA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results